Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
27,795,576
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
27,689,979
-
Shares change
-
-673,068
-
Total reported value, excl. options
-
$209,893,010
-
Value change
-
-$8,354,009
-
Put/Call ratio
-
1373%
-
Number of buys
-
55
-
Number of sells
-
-34
-
Price
-
$7.58
Significant Holders of Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) as of Q4 2020
133 filings reported holding AXDX - Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share as of Q4 2020.
Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27,689,979 shares
of 27,795,576 outstanding shares and own 100% of the company stock.
Largest 10 shareholders include ORACLE INVESTMENT MANAGEMENT INC (3,806,139 shares), BlackRock Inc. (2,304,788 shares), Birchview Capital, LP (2,193,795 shares), CREDIT SUISSE AG/ (1,765,362 shares), AXA S.A. (1,659,062 shares), VANGUARD GROUP INC (1,649,825 shares), Chicago Capital, LLC (1,608,235 shares), GRIFFIN ASSET MANAGEMENT, INC. (1,469,820 shares), FMR LLC (1,438,010 shares), and CANNELL PETER B & CO INC (1,113,239 shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.